Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Betaferon opvejer risiciene til behandling af patienter med attakvis dissemineret sklerose og patienter med sekundær progressiv dissemineret sklerose samt patienter med en enkelt demyeliniserende hændelse af en sværhedsgrad, der berettiger behandling med injektion af cortikosteroider.
The Committee for Medicinal products for Human Use (CHMP) decided that Betaferon’ s benefits are greater than its risks for the treatment of patients with relapsing remitting multiple sclerosis, secondary progressive multiple sclerosis, and in patients with a single episode of demyelination, severe enough to justify treatment with injected corticosteroids.